Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...
Xeris Biopharma: Low Risk, Low Excitement Solid Revenue Generator
Explore Xeris Biopharma's revenue growth, promising pipeline, & thriving products. Learn about their strong outlook & ...
Fox Business6d
Novo Nordisk shares fall on weight-loss drug trial
Shares of Novo Nordisk slipped in Monday morning trading ... a synthetic version of the hormone amylin, which is released by the pancreas. Cagrilintide is currently being developed in combination ...
MedPage Today on MSN5d
Endocrine Society's New President-Elect; Judge Stops Compounders; New GLP-1 Benefits
Falling short of expectations, Novo Nordisk said its investigational fixed-dose combination of cagrilintide and semaglutide ...
Healthy Returns: Wegovy is linked to an increased risk of hair loss, study suggests
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
The State of Weight Loss Drugs
How weight loss drugs actually work, and how big-name prescriptions differ from each other. What investors need to know about ...
pharmaphorum6d
Novo Nordisk launches recycling programme for pen injectors
The new PenCycle programme covers Novo Nordisk's FlexPen and FlexTouch ... and an 'at home' collection service for people using growth hormone pens. "These pens are made from high-quality, long ...
This Top Dividend Stock Just Entered The Weight Loss Market: Is It a Buy?
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...